PharmaCyte Biotech Inc (PMCB)

[Alydyr]

The SEC has contacted NVLX - Not good

Per the Amended 10-K/A filing issued today on the SEC.gov website.....

Explanatory Note

We are filing this amendment to our annual report on Form 10-K for the year ended April 30, 2014 (“10-K”) to amend Part I, Item 1 - Business and Part III, Item 13 Certain Relationships and Related Transactions, and Director Independence, in the original 10-K filed with the Securities and Exchange Commission (“SEC”), in response to comments from the staff of the SEC. Except as aforesaid, the information in this Form 10-K/A has not been updated to reflect events that occurred after August 4, 2014, the filing date of the original 10-K. Accordingly, this Form 10-K/A should be read in conjunction with the 10-K and our filings made with the SEC subsequent thereto. Except as set forth above, all other information in the 10-K remains unchanged. The Company has included as exhibits to this Form 10-K/A an updated certification from the Company’s Principal Executive and Financial Officer pursuant to Sections 302 and 906 of the Sarbanes Oxley Act of 2002 and certain additional exhibits pursuant to comments from the staff of the SEC.

http://www.sec.gov/Archives/edgar/data/1157075/000101968714003893/nuvilex_10ka.htm